Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO Sells $103,475.00 in Stock

Posted by Brenda Bartman on Sep 26th, 2026

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William Peters sold 4,139 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $25.00, for a total transaction of $103,475.00. Following the completion of the sale, the chief financial officer directly owned 168,707 shares in the company, valued at $4,217,675. This trade represents a 2.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH opened at $26.13 on Friday. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 15.46, a price-to-earnings-growth ratio of 5.06 and a beta of 0.92. The company’s 50-day moving average is $21.87 and its two-hundred day moving average is $20.53. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $29.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.62 by $0.29. The company had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on AMPH. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Wells Fargo & Company lifted their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Bank of America restated an “underperform” rating and set a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Finally, Wall Street Zen lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 12th. Six analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Reduce” and a consensus price target of $22.50.

Get Our Latest Report on AMPH

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at $609,000. Squarepoint Ops LLC increased its holdings in shares of Amphastar Pharmaceuticals by 178.0% during the 2nd quarter. Squarepoint Ops LLC now owns 78,795 shares of the company’s stock valued at $1,590,000 after acquiring an additional 50,450 shares during the last quarter. Empowered Funds LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at approximately $3,286,000. Bank of America Corp DE acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at $2,761,000. Finally, Man Group plc bought a new position in shares of Amphastar Pharmaceuticals in the second quarter worth about $350,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.